UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 13, 2003
ULTRALIFE BATTERIES, INC.
-------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------
(State or other jurisdiction of incorporation or organization)
0-20852 16-1387013
------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
- ------------------------ ------------------------------------
2000 Technology Parkway, Newark, New York 14513
-----------------------------------------------
(Address of principal executive offices) (Zip Code)
(315) 332-7100
--------------
(Registrant's telephone number, including area code)
1
Item 7. Financial Statements, Pro Forma Financials and Exhibits.
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
99.1 Press Release dated August 13, 2003
Item 9. Regulation FD Disclosure.
The Company announced the receipt of a $2.9 million order for its lithium Thin
Cell(R) batteries from an undisclosed U. S. medical device maker. Cell
deliveries are expected to begin in September and extend into 2004. Refer to the
attached Exhibit 99.1 for the entire text of the release, which Exhibit is being
furnished but not filed in accordance with Regulation FD.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ULTRALIFE BATTERIES, INC.
Dated: August 13, 2003 By: /s/Peter F. Comerford
----------------------------------
Peter F. Comerford
Vice President - Administration &
General Counsel
2
Index to Exhibits
(99) Additional Exhibits
99.1 Press Release dated August 13, 2003
3
Exhibit 99.1
Company Contact:
Ultralife Batteries, Inc.
Peter Comerford
(315) 332-7100
pcomerford@ulbi.com
Investor Relations Contact:
Lippert/Heilshorn & Associates, Inc.
Jody Burfening
(212) 838-3777
jks@lhai.com
Media Contact:
Lippert/Heilshorn & Associates, Inc.
Chenoa Taitt
(212) 201-6635
ctaitt@lhai.com
Ultralife Batteries, Inc. Receives $2.9 Million Lithium Thin Cell Battery Order
for Medical Application
Newark, New York - August 13, 2003 - Ultralife Batteries, Inc. (NASDAQ: ULBI),
today announced the receipt of a $2.9 million order for its lithium Thin
Cell(R)batteries from an undisclosed U.S. medical device maker. Cell deliveries
are expected to begin in September and extend into 2004.
John D. Kavazanjian, Ultralife's president and chief executive officer, said,
"We are very pleased to receive this order, which illustrates the growth
opportunities available to Ultralife in the medical device field, one of our
target markets. Our Thin Cell products offer unparalleled flexibility to
designers in diverse applications such as medical devices and other thin-profile
products."
Nancy N. Naigle, Ultralife's vice president of sales and marketing, said,
"Interest in our Thin Cell products has been growing and we expect to see
continued demand for their use in a range of innovative applications, many of
which are enabled by the unique characteristics of our thin battery technology."
The new medical device is powered by a custom-designed lithium Thin Cell less
than one-eighth inch thick and weighing only one-half ounce.
Ultralife's lithium-manganese dioxide (non-rechargeable) Thin Cell batteries
provide a unique combination of thin profile, light weight, high energy, long
life and wide operating temperature range. With their ultra-thin prismatic form
and a high ratio of active materials to packaging, Thin Cells can efficiently
fill virtually any battery cavity. Typical applications for these batteries
include flat-profile products such as: medical devices, security access cards,
wireless tracking tags, bank theft tracking systems and any application
requiring a thin, lightweight, high-energy power source.
About Ultralife Batteries, Inc.
Ultralife is a leading developer, manufacturer, and marketer of standard and
customized lithium primary (non-rechargeable), lithium ion and lithium polymer
rechargeable batteries. Ultralife's high-energy batteries use advanced lithium
technology and are used in military, industrial and consumer portable electronic
products. Through its range of standard products and ability to customize for a
wide range of applications, Ultralife is able to provide the next generation of
battery solutions. OEM, retail and government customers include Energizer, Kidde
Safety, Philips Medical Systems, Radio Shack and the national defense agencies
of the United States and United Kingdom, among others.
Ultralife's headquarters, principal manufacturing and research facilities are in
Newark, New York, near Rochester. Ultralife (UK) Ltd., a second manufacturing
and research facility, is located in Abingdon, U.K. Both facilities are
ISO-9001/2000 certified.
- Continued -
4
Page 2
This press release may contain forward-looking statements based on current
expectations that involve a number of risks and uncertainties. The potential
risks and uncertainties that could cause actual results to differ materially
include: worsening global economic conditions, increased competitive environment
and pricing pressures, disruptions related to restructuring actions and delays.
Further information on these factors and other factors that could affect
Ultralife's financial results is included in Ultralife's Securities and Exchange
Commission (SEC) filings, including the latest Annual Report on Form 10-K.
Detailed information on Ultralife is available at the Company's web site,
www.ultralifebatteries.com.
Ultralife(R)and Ultralife Thin Cell(R)are registered trademarks of Ultralife
Batteries, Inc.
###
5